Anti Cd 20 Ocrevus denied as non-formulary by Aetna?

Aetna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Ocrevus as Non-Formulary

A non-formulary denial means Ocrevus (ocrelizumab) does not appear on Aetna's current formulary tier for your specific plan, or appears only at a tier that requires additional authorization steps. Formulary placement is plan-specific — it varies by employer group, marketplace plan year, and geographic market. The drug itself is FDA-approved; the issue is purely administrative placement within your benefit design.

Non-formulary denials are appealed through two distinct pathways: a formulary exception (asking Aetna to cover the drug as if it were on-formulary) and the standard internal/external appeal chain. Formulary exceptions succeed most often when the patient has a documented clinical reason they cannot use the formulary alternatives.

## Federal Appeal Rights

• Formulary exception request: File this first — it is faster than a full appeal. You must show that every formulary alternative is contraindicated, has been tried and failed, or is otherwise clinically inappropriate for this patient. Your neurologist's letter is essential.
• Internal appeal: Under ERISA §503 or ACA rules, a formal internal appeal runs on the timeline stated in your denial letter.
• External review: Under ACA §2719, if the internal appeal and exception request both fail, external review by an IRO is available. The window is approximately four months from the final adverse determination.
• Expedited review: Available when standard timelines would jeopardize health.

## What to Gather

1. Formulary alternative history — for each disease-modifying therapy on Aetna's current MS formulary, document whether it was tried (with dates and outcomes) or why it is not appropriate for this patient (intolerance, contraindication per the prescriber, or lack of approval for this patient's MS subtype). 2. MS subtype documentation — if Ocrevus is sought for primary progressive MS, note that formulary alternatives may not share this FDA indication; that distinction is powerful for an exception request. 3. Diagnosis and disease-activity records — current MRI, relapse history, functional status. 4. Prescriber medical-necessity and exception letter — the letter should address each formulary alternative by name, state why it is not appropriate, and explain why Ocrevus specifically is required. 5. Aetna's formulary and exception policy — download the current plan formulary and Aetna's formulary exception criteria. Map each exception criterion to documentation.

## Criteria-Mapping Structure

| Exception Criterion | Documentation | |---|---| | Formulary alternative A tried and failed | Medication history: dates, documented reason for stop | | Formulary alternative B contraindicated or not approved for subtype | Prescriber letter; FDA label for alternative | | Ocrevus approved for this patient's specific MS subtype | FDA label; diagnosis confirmation | | Clinical urgency (if expedited) | Neurologist statement of health risk |

Attach the FDA label for Ocrevus as Exhibit A, particularly the indication section. If formulary alternatives lack approval for the patient's MS subtype (e.g., PPMS), this is often the single most compelling argument for a formulary exception.